Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects (MAPPAC)
Acute Appendicitis
About this trial
This is an interventional other trial for Acute Appendicitis focused on measuring Uncomplicated acute appendicitis, Complicated acute appendicitis, Antibiotic therapy, Microbiological etiology
Eligibility Criteria
Inclusion Criteria:
- Age 18-60 years
- CT confirmed uncomplicated or complicated acute appendicitis
- Ability to give consent to participate in the study
Exclusion Criteria:
- Age under 18 years or over 60 years
- Pregnancy or lactation
- Allergy to contrast media or iodine
- Allergy or contraindication to antibiotic therapy
- Renal insufficiency
- Metformin medication
- Severe systemic illness (for example malignancy, medical condition requiring immunosuppressant medication)
- Inability to co-operate and give informed consent
Sites / Locations
- Turku University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Active Comparator
Active Comparator
Placebo Comparator
Other
Other
Active Comparator
I.v. + p.o. antibiotics (APPAC II)
P.o. moxifloxacin (APPAC II)
Placebo treatment (APPAC III)
Surgery (complicated appendicitis)
Surgery (uncomplicated appendicitis)
I.v. + p.o. antibiotics (APPAC III)
Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.